ArticleTherapeutic advances in medical oncology2025

Comparative real-world outcomes of stage III melanoma patients treated with talimogene laherparepvec or interleukin 2.

Markus Reitmajer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.